Humacyte (NASDAQ:HUMA) Given New $10.00 Price Target at Benchmark

Humacyte (NASDAQ:HUMA) had its price objective trimmed by Benchmark from $11.00 to $10.00 in a research report report published on Wednesday, Marketbeat.com reports. They currently have a buy rating on the stock.

Several other brokerages also recently commented on HUMA. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Humacyte in a research note on Monday, December 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. UBS Group restated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. BTIG Research reaffirmed a “buy” rating and set a $6.00 price objective on shares of Humacyte in a report on Friday, November 21st. Finally, Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.14.

Humacyte Stock Down 3.9%

NASDAQ HUMA opened at $0.98 on Wednesday. Humacyte has a 1-year low of $0.91 and a 1-year high of $4.85. The company has a market capitalization of $183.52 million, a price-to-earnings ratio of -4.26 and a beta of 1.93. The stock’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.60. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. The company had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.92 million. Equities analysts forecast that Humacyte will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humacyte

Large investors have recently modified their holdings of the stock. Pallas Capital Advisors LLC acquired a new stake in shares of Humacyte in the second quarter valued at approximately $42,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Humacyte in the 2nd quarter valued at $49,000. Wealth Effects LLC raised its position in shares of Humacyte by 5.8% during the second quarter. Wealth Effects LLC now owns 102,167 shares of the company’s stock worth $214,000 after acquiring an additional 5,600 shares during the last quarter. Lazari Capital Management Inc. bought a new stake in shares of Humacyte during the second quarter worth $27,000. Finally, Archford Capital Strategies LLC acquired a new position in shares of Humacyte during the second quarter valued at $42,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.